# Survey of Neuromodulator Use for Optimization of Facial Scars and Blepharoplasty and Brow Lift Outcomes

**Authors:** Manoj T Abraham, Solomon Husain, Anni Wong, Sunder Gidumal, Ebrahim Elahi, Ellen Marmur, Matthew DelMauro

PMC · DOI: 10.1093/asjof/ojaf005 · Aesthetic Surgery Journal. Open Forum · 2025-01-16

## TL;DR

This survey explores how often surgeons use neuromodulators to improve facial scar appearance and outcomes of blepharoplasty and brow lift surgeries.

## Contribution

The study provides new insights into the current usage patterns of neuromodulators across surgical subspecialties for facial aesthetic procedures.

## Key findings

- 96.7% of surveyed surgeons use neuromodulators in their practice.
- Only 21% use neuromodulators for scar optimization, and 12.3% and 25.4% for blepharoplasty and brow lift outcomes, respectively.
- Despite potential benefits, neuromodulator use for these procedures remains limited among respondents.

## Abstract

There are many published studies that indicate neuromodulators help improve surgical outcomes and the appearance of facial scars.

To determine the prevalence of neuromodulator use as an adjunct for facial scar treatment as well as blepharoplasty and brow lift surgeries across surgical subspecialties.

An anonymous electronic survey was distributed to plastic surgeons, facial plastic surgeons, oculoplastic surgeons, and dermatologic surgeons through their respective national societies. The survey assessed demographics, practice characteristics, and practice habits.

A total of 276 surgeons responded. Although 96.7% of respondents use neuromodulators in their practice, only 21% utilize neuromodulators for scar optimization, and 12.3% and 25.4% utilize neuromodulators for optimization of blepharoplasty and surgical brow lift outcomes, respectively.

Although the use of neuromodulators has been shown to improve the appearance of scars and could enhance outcomes after blepharoplasty and brow lift procedures, its use among respondents was limited.

## Full-text entities

- **Diseases:** muscle paralysis (MESH:D012133), hyperpigmentation (MESH:D017495), Facial scars (MESH:D002921), injury to the frontal branch of the facial nerve (MESH:D020220), hypertrophy (MESH:D006984), frontalis hyperactivity (MESH:D006957)
- **Chemicals:** acetylcholine (MESH:D000109), silicone (MESH:D012828)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11842229/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11842229/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC11842229/full.md

---
Source: https://tomesphere.com/paper/PMC11842229